Imaging lung cancer using a novel dual-target agent
A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
EARLY_PHASE1 · Peking Union Medical College Hospital · NCT05543954
This study is testing a new imaging agent to see if it can help doctors get a better look at lung cancer compared to standard imaging methods.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05543954 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a new imaging agent, 68Ga-FAPI-RGD, for PET/CT imaging in patients with lung cancer. It aims to improve the visualization of lung cancer lesions by targeting specific receptors that are highly expressed in cancerous tissues and their associated blood vessels. The study compares the dual-target imaging approach with conventional methods like 18F-FDG PET/CT and single-target imaging agents. By utilizing this novel imaging technique, the study seeks to enhance diagnostic accuracy and assist in the management of lung cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with confirmed or suspected lung cancer who can undergo PET/CT imaging.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could lead to more accurate diagnoses and better treatment planning for lung cancer patients.
How similar studies have performed: While conventional imaging methods have been widely used, this dual-target approach is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with confirmed or suspected lung cancer; * 68Ga-FAPI-RGD and 18F-FDG(or 68Ga-FAPI or 68Ga-RGD) PET/CT within 2 week; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing
- Peking Union Medical College Hospital — Beijing, China (RECRUITING)
Study contacts
- Principal investigator: Zhaohui Zhu, MD,PHD — Peking Union Medical College Hospital
- Study coordinator: Zhaohui Zhu, MD,PHD
- Email: 13611093752@163.com
- Phone: 86+13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Neoplasms